Skip to main content
Erschienen in: Digestive Diseases and Sciences 6/2022

21.05.2021 | Review

Patient Perspectives and Expectations in Inflammatory Bowel Disease: A Systematic Review

verfasst von: Alex Al Khoury, Bhairavi Balram, Talat Bessissow, Waqqas Afif, Lorant Gonczi, Maria Abreu, Peter L. Lakatos

Erschienen in: Digestive Diseases and Sciences | Ausgabe 6/2022

Einloggen, um Zugang zu erhalten

Abstract

Background

In this systematic review, our objective was to assess inflammatory bowel disease (IBD) patient preferences and perspectives relating to their disease diagnosis, treatment, knowledge needs and telemedicine.

Methods

This study was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. Four databases and conference proceedings were searched between January 1, 1980, and May 1, 2020. The methodological quality of the included studies was assessed using the Standards for reporting qualitative research checklist.

Results

Our search identified 240 citations and 52 studies met the inclusion criteria. The major expectations of the patients are symptomatic and pain control, quality of life and normal endoscopy. Patients’ main concerns are access to information and healthcare, and shared decision making. At the time of diagnosis, patients expressed a greater need for knowledge about their IBD, preferentially by their treating gastroenterologist. The main treatment expectations in active disease are efficacy, safety and convenience. Patients are willing to accept relatively high risks of complications from medical therapy to avoid a permanent ostomy and to achieve durable remission. Patients are more interested in disease monitoring, research and development during the time of remission. Telemedicine and self-management with supervised e-health tools are feasible and acceptable amongst patients with IBD.

Conclusion

This systematic review demonstrates that patients with IBD expect more information about their disease process, shared decision making and symptom control. Further research is needed to help align patient and physician expectations in order to improve the quality of care provided to patients with IBD.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Barreiro-de Acosta M et al. P639 Influence of extraintestinal manifestations in health-related quality of life in inflammatory bowel disease patients. J Crohn’s and Colitis 2013;7:S266–S267.CrossRef Barreiro-de Acosta M et al. P639 Influence of extraintestinal manifestations in health-related quality of life in inflammatory bowel disease patients. J Crohn’s and Colitis 2013;7:S266–S267.CrossRef
2.
Zurück zum Zitat Ng SC et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. Lancet 2018;390:2769–2778.CrossRef Ng SC et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. Lancet 2018;390:2769–2778.CrossRef
3.
Zurück zum Zitat Colombel JF et al. Effect of tight control management on Crohn’s disease (CALM): a multicentre, randomised, controlled phase 3 trial. Lancet 2018;390:2779–2789.CrossRef Colombel JF et al. Effect of tight control management on Crohn’s disease (CALM): a multicentre, randomised, controlled phase 3 trial. Lancet 2018;390:2779–2789.CrossRef
4.
Zurück zum Zitat Colombel JF et al. Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis. Gastroenterology 2011;141:1194–1201.PubMedCrossRef Colombel JF et al. Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis. Gastroenterology 2011;141:1194–1201.PubMedCrossRef
5.
Zurück zum Zitat Frøslie KF et al. Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort. Gastroenterology 2007;133:412–422.PubMedCrossRef Frøslie KF et al. Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort. Gastroenterology 2007;133:412–422.PubMedCrossRef
6.
Zurück zum Zitat Shah SC et al. Mucosal healing is associated with improved long-term outcomes of patients with ulcerative colitis: a systematic review and meta-analysis. Clin Gastroenterol Hepatol 2016;14:1245-1255.e8.PubMedCrossRef Shah SC et al. Mucosal healing is associated with improved long-term outcomes of patients with ulcerative colitis: a systematic review and meta-analysis. Clin Gastroenterol Hepatol 2016;14:1245-1255.e8.PubMedCrossRef
7.
Zurück zum Zitat Shah SC et al. Systematic review with meta-analysis: mucosal healing is associated with improved long-term outcomes in Crohn’s disease. Aliment Pharmacol Ther 2016;43:317–333.PubMedCrossRef Shah SC et al. Systematic review with meta-analysis: mucosal healing is associated with improved long-term outcomes in Crohn’s disease. Aliment Pharmacol Ther 2016;43:317–333.PubMedCrossRef
8.
Zurück zum Zitat Turner D et al. STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD. Gastroenterology, 2020. Turner D et al. STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD. Gastroenterology, 2020.
9.
Zurück zum Zitat Danese S et al. Unmet medical needs in ulcerative colitis: an expert group consensus. Dig Dis 2019;37:266–283.PubMedCrossRef Danese S et al. Unmet medical needs in ulcerative colitis: an expert group consensus. Dig Dis 2019;37:266–283.PubMedCrossRef
10.
Zurück zum Zitat Hindryckx P et al. Incidence, prevention and management of anti-drug antibodies against therapeutic antibodies in inflammatory bowel disease: a practical overview. Drugs 2017;77:363–377.PubMedCrossRef Hindryckx P et al. Incidence, prevention and management of anti-drug antibodies against therapeutic antibodies in inflammatory bowel disease: a practical overview. Drugs 2017;77:363–377.PubMedCrossRef
11.
Zurück zum Zitat Moss AC, Brinks V, Carpenter JF. Review article: immunogenicity of anti-TNF biologics in IBD - the role of patient, product and prescriber factors. Aliment Pharmacol Ther 2013;38:1188–1197.PubMedCrossRef Moss AC, Brinks V, Carpenter JF. Review article: immunogenicity of anti-TNF biologics in IBD - the role of patient, product and prescriber factors. Aliment Pharmacol Ther 2013;38:1188–1197.PubMedCrossRef
12.
Zurück zum Zitat Rutgeerts P et al. Efficacy of ustekinumab for inducing endoscopic healing in patients with Crohn’s disease. Gastroenterology 2018;155:1045–1058.PubMedCrossRef Rutgeerts P et al. Efficacy of ustekinumab for inducing endoscopic healing in patients with Crohn’s disease. Gastroenterology 2018;155:1045–1058.PubMedCrossRef
13.
Zurück zum Zitat D'Amico F et al. Tofacitinib in the treatment of ulcerative colitis: efficacy and safety from clinical trials to real-world experience. Therap Adv Gastroenterol, 2019. 12. D'Amico F et al. Tofacitinib in the treatment of ulcerative colitis: efficacy and safety from clinical trials to real-world experience. Therap Adv Gastroenterol, 2019. 12.
14.
Zurück zum Zitat Fiorino G et al. Quality of care standards in inflammatory bowel diseases: a European Crohn’s and colitis organisation [ECCO] position paper. J Crohns Colitis 2020;14:1037–1048.PubMedCrossRef Fiorino G et al. Quality of care standards in inflammatory bowel diseases: a European Crohn’s and colitis organisation [ECCO] position paper. J Crohns Colitis 2020;14:1037–1048.PubMedCrossRef
15.
Zurück zum Zitat Morishige R et al. Preferences regarding shared decision-making in Japanese inflammatory bowel disease patients. Adv Therapy 2017;33:2242–2256.CrossRef Morishige R et al. Preferences regarding shared decision-making in Japanese inflammatory bowel disease patients. Adv Therapy 2017;33:2242–2256.CrossRef
16.
Zurück zum Zitat Bitton A et al. Selection of quality Indicators in IBD: integrating physician and patient perspectives. Inflammatory Bowel Diseases 2019;25:403–409.PubMedCrossRef Bitton A et al. Selection of quality Indicators in IBD: integrating physician and patient perspectives. Inflammatory Bowel Diseases 2019;25:403–409.PubMedCrossRef
17.
Zurück zum Zitat Hodgkins P et al. Patient preferences for first-line oral treatment for mild-to-moderate ulcerative colitis: a discrete-choice experiment. The patient 2012;5:33–44.PubMedCrossRef Hodgkins P et al. Patient preferences for first-line oral treatment for mild-to-moderate ulcerative colitis: a discrete-choice experiment. The patient 2012;5:33–44.PubMedCrossRef
18.
Zurück zum Zitat Gray JR, Leung E, Scales J. Treatment of ulcerative colitis from the patient’s perspective: a survey of preferences and satisfaction with therapy. Aliment Pharmacol Ther 2009;29:1114–1120.PubMedCrossRef Gray JR, Leung E, Scales J. Treatment of ulcerative colitis from the patient’s perspective: a survey of preferences and satisfaction with therapy. Aliment Pharmacol Ther 2009;29:1114–1120.PubMedCrossRef
19.
21.
Zurück zum Zitat Keil R et al. Adherence, risk factors of non-adherence and patient’s preferred treatment strategy of mesalazine in ulcerative colitis: multicentric observational study. Scand J Gastroenterol 2018;53:459–465.PubMedCrossRef Keil R et al. Adherence, risk factors of non-adherence and patient’s preferred treatment strategy of mesalazine in ulcerative colitis: multicentric observational study. Scand J Gastroenterol 2018;53:459–465.PubMedCrossRef
22.
Zurück zum Zitat Bewtra M, Johnson FR. Assessing patient preferences for treatment options and process of care in inflammatory bowel disease: a critical review of quantitative data. The patient 2013;6:241–255.PubMedCrossRef Bewtra M, Johnson FR. Assessing patient preferences for treatment options and process of care in inflammatory bowel disease: a critical review of quantitative data. The patient 2013;6:241–255.PubMedCrossRef
23.
Zurück zum Zitat Moher D, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Int Med 2009;151:264–269.PubMedCrossRef Moher D, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Int Med 2009;151:264–269.PubMedCrossRef
24.
Zurück zum Zitat O’Brien BC, Beckman TJ, Reed DA, Cook DA. Standards for reporting qualitative research: a synthesis of recommendations. Acad Med. 2014;89:1245–1251.PubMedCrossRef O’Brien BC, Beckman TJ, Reed DA, Cook DA. Standards for reporting qualitative research: a synthesis of recommendations. Acad Med. 2014;89:1245–1251.PubMedCrossRef
25.
Zurück zum Zitat Casellas F et al. Patient preferences for inflammatory bowel disease treatment objectives. Digest Liver Dis Off J Ital Soc Gastroenterol Ital Assoc Study Liver 2017;49:152–156. Casellas F et al. Patient preferences for inflammatory bowel disease treatment objectives. Digest Liver Dis Off J Ital Soc Gastroenterol Ital Assoc Study Liver 2017;49:152–156.
26.
Zurück zum Zitat Li SX et al. Delivering high value inflammatory bowel disease care through telemedicine visits. Inflamm Bowel Dis 2017;23:1678–1681.PubMedCrossRef Li SX et al. Delivering high value inflammatory bowel disease care through telemedicine visits. Inflamm Bowel Dis 2017;23:1678–1681.PubMedCrossRef
27.
Zurück zum Zitat de Jong MJ et al. Telemedicine for management of inflammatory bowel disease (myIBDcoach): a pragmatic, multicentre, randomised controlled trial. Lancet 2017;390:959–968.PubMedCrossRef de Jong MJ et al. Telemedicine for management of inflammatory bowel disease (myIBDcoach): a pragmatic, multicentre, randomised controlled trial. Lancet 2017;390:959–968.PubMedCrossRef
28.
Zurück zum Zitat Elkjaer M et al. E-health empowers patients with ulcerative colitis: a randomised controlled trial of the web-guided “Constant-care” approach. Gut 2010;59:1652–1661.PubMedCrossRef Elkjaer M et al. E-health empowers patients with ulcerative colitis: a randomised controlled trial of the web-guided “Constant-care” approach. Gut 2010;59:1652–1661.PubMedCrossRef
30.
Zurück zum Zitat Hagelund LM, Elkjær Stallknecht S, Jensen HH, Quality of life and patient preferences among Danish patients with ulcerative colitis - results from a survey study. Curr Med Res Opin 2020:1–9. Hagelund LM, Elkjær Stallknecht S, Jensen HH, Quality of life and patient preferences among Danish patients with ulcerative colitis - results from a survey study. Curr Med Res Opin 2020:1–9.
31.
Zurück zum Zitat Cross RK et al. A randomized controlled trial of telemedicine for patients with inflammatory bowel disease (TELE-IBD). Am J Gastroenterol 2019;114:472–482.PubMedCrossRef Cross RK et al. A randomized controlled trial of telemedicine for patients with inflammatory bowel disease (TELE-IBD). Am J Gastroenterol 2019;114:472–482.PubMedCrossRef
32.
Zurück zum Zitat Arseneau KO et al. Do patient preferences influence decisions on treatment for patients with steroid-refractory ulcerative colitis? Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc 2006;4:1135–1142. Arseneau KO et al. Do patient preferences influence decisions on treatment for patients with steroid-refractory ulcerative colitis? Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc 2006;4:1135–1142.
33.
Zurück zum Zitat Casellas F et al. Patients’ perceptions, attitudes, and experiences about the management of mild-to-moderate ulcerative colitis. J Crohns Colitis 2014;8:1097–1107.PubMedCrossRef Casellas F et al. Patients’ perceptions, attitudes, and experiences about the management of mild-to-moderate ulcerative colitis. J Crohns Colitis 2014;8:1097–1107.PubMedCrossRef
34.
Zurück zum Zitat Daher S et al. Inflammatory bowel disease patient profiles are related to specific information needs: A nationwide survey. World J Gastroenterol 2019;25:4246–4260.PubMedPubMedCentralCrossRef Daher S et al. Inflammatory bowel disease patient profiles are related to specific information needs: A nationwide survey. World J Gastroenterol 2019;25:4246–4260.PubMedPubMedCentralCrossRef
35.
Zurück zum Zitat Bernstein KI et al. Information needs and preferences of recently diagnosed patients with inflammatory bowel disease. Inflamm Bowel Dis 2011;17:590–598.PubMedCrossRef Bernstein KI et al. Information needs and preferences of recently diagnosed patients with inflammatory bowel disease. Inflamm Bowel Dis 2011;17:590–598.PubMedCrossRef
36.
Zurück zum Zitat Lesnovska KP et al. What do patients need to know? Living with inflammatory bowel disease. J Clin Nurs 2014;23:1718–1725.PubMedCrossRef Lesnovska KP et al. What do patients need to know? Living with inflammatory bowel disease. J Clin Nurs 2014;23:1718–1725.PubMedCrossRef
37.
Zurück zum Zitat Almario CV et al. Optimizing selection of biologics in inflammatory bowel disease: development of an online patient decision aid using conjoint analysis. Am J Gastroenterol 2018;113:58–71.PubMedCrossRef Almario CV et al. Optimizing selection of biologics in inflammatory bowel disease: development of an online patient decision aid using conjoint analysis. Am J Gastroenterol 2018;113:58–71.PubMedCrossRef
38.
Zurück zum Zitat Boeri M et al. Patient and physician preferences for ulcerative colitis treatments in the United States. Clin Exp Gastroenterol 2019;12:263–278.PubMedPubMedCentralCrossRef Boeri M et al. Patient and physician preferences for ulcerative colitis treatments in the United States. Clin Exp Gastroenterol 2019;12:263–278.PubMedPubMedCentralCrossRef
39.
Zurück zum Zitat Bewtra M et al. Variation among patients With Crohn’s disease in benefit vs risk preferences and remission time equivalents. Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc 2020;18:406. Bewtra M et al. Variation among patients With Crohn’s disease in benefit vs risk preferences and remission time equivalents. Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc 2020;18:406.
40.
Zurück zum Zitat Bewtra M et al. Patient preferences for surgical versus medical therapy for ulcerative colitis. Inflamm Bowel Dis 2014;20:103–114.PubMedCrossRef Bewtra M et al. Patient preferences for surgical versus medical therapy for ulcerative colitis. Inflamm Bowel Dis 2014;20:103–114.PubMedCrossRef
41.
Zurück zum Zitat Casellas F, Ginard D, Riestra S. Patient satisfaction in the management of mild-to-moderate ulcerative colitis: Results of a Delphi study among patients and physicians. Digest Liver Dis Off J Ital Soc Gastroenterol Ital Assoc Study Liver 2016;48:1172–1179. Casellas F, Ginard D, Riestra S. Patient satisfaction in the management of mild-to-moderate ulcerative colitis: Results of a Delphi study among patients and physicians. Digest Liver Dis Off J Ital Soc Gastroenterol Ital Assoc Study Liver 2016;48:1172–1179.
42.
Zurück zum Zitat Gregor JC et al. Inflammatory bowel disease patients prioritize mucosal healing, symptom control, and pain when choosing therapies: results of a prospective cross-sectional willingness-to-pay study. Patient Prefer Adherence 2018;12:505–513.PubMedPubMedCentralCrossRef Gregor JC et al. Inflammatory bowel disease patients prioritize mucosal healing, symptom control, and pain when choosing therapies: results of a prospective cross-sectional willingness-to-pay study. Patient Prefer Adherence 2018;12:505–513.PubMedPubMedCentralCrossRef
43.
Zurück zum Zitat Johnson FR et al. Crohn’s disease patients’ risk-benefit preferences: serious adverse event risks versus treatment efficacy. Gastroenterology 2007;133:769–779.PubMedCrossRef Johnson FR et al. Crohn’s disease patients’ risk-benefit preferences: serious adverse event risks versus treatment efficacy. Gastroenterology 2007;133:769–779.PubMedCrossRef
44.
Zurück zum Zitat Johnson FR et al. Are gastroenterologists less tolerant of treatment risks than patients? Benefit-risk preferences in Crohn’s disease management. J Manage Care Pharm JMCP 2010;16:616–628. Johnson FR et al. Are gastroenterologists less tolerant of treatment risks than patients? Benefit-risk preferences in Crohn’s disease management. J Manage Care Pharm JMCP 2010;16:616–628.
45.
Zurück zum Zitat Lai C et al. Patient decision-making in severe inflammatory bowel disease: the need for improved communication of treatment options and preferences. Colorectal Dis Off J Assoc Coloproctol Great Brit Ireland 2019;21:1406–1414.CrossRef Lai C et al. Patient decision-making in severe inflammatory bowel disease: the need for improved communication of treatment options and preferences. Colorectal Dis Off J Assoc Coloproctol Great Brit Ireland 2019;21:1406–1414.CrossRef
46.
Zurück zum Zitat Peake STC et al. Patient preference in choosing biological therapy in Crohn’s disease. Inflamm Bowel Dis 2011;17:E79.PubMedCrossRef Peake STC et al. Patient preference in choosing biological therapy in Crohn’s disease. Inflamm Bowel Dis 2011;17:E79.PubMedCrossRef
47.
Zurück zum Zitat Loftus EV Jr. A practical perspective on ulcerative colitis: patients’ needs from aminosalicylate therapies. Inflamm Bowel Dis 2006;12:1107–1113.PubMedCrossRef Loftus EV Jr. A practical perspective on ulcerative colitis: patients’ needs from aminosalicylate therapies. Inflamm Bowel Dis 2006;12:1107–1113.PubMedCrossRef
48.
Zurück zum Zitat Peyrin-Biroulet L et al. Treatment satisfaction, preferences and perception gaps between patients and physicians in the ulcerative colitis CARES study: A real world-based study. Digest Liver Dis Off J Ital Soc Gastroenterol Ital Assoc Study Liver 2016;48:601–607. Peyrin-Biroulet L et al. Treatment satisfaction, preferences and perception gaps between patients and physicians in the ulcerative colitis CARES study: A real world-based study. Digest Liver Dis Off J Ital Soc Gastroenterol Ital Assoc Study Liver 2016;48:601–607.
49.
Zurück zum Zitat Lichtenstein G, Kelly J, McDonald SS, Zanutto EL, Hendricks D, Rahman MI. Assessing drug treatment preferences of patients with Crohn’s disease. PatientPatient-Cent Outcomes Res 2010;3:113–123.CrossRef Lichtenstein G, Kelly J, McDonald SS, Zanutto EL, Hendricks D, Rahman MI. Assessing drug treatment preferences of patients with Crohn’s disease. PatientPatient-Cent Outcomes Res 2010;3:113–123.CrossRef
50.
Zurück zum Zitat Barsky M et al, understanding determinants of patient preferences between stool tests and colonoscopy for the assessment of disease activity in inflammatory bowel disease. Dig Dis Sci 2020. Barsky M et al, understanding determinants of patient preferences between stool tests and colonoscopy for the assessment of disease activity in inflammatory bowel disease. Dig Dis Sci 2020.
51.
Zurück zum Zitat Noiseux I et al. Inflammatory bowel disease patient perceptions of diagnostic and monitoring tests and procedures. BMC Gastroenterology 2019;19(1):N.PAG-N.PAG. Noiseux I et al. Inflammatory bowel disease patient perceptions of diagnostic and monitoring tests and procedures. BMC Gastroenterology 2019;19(1):N.PAG-N.PAG.
52.
Zurück zum Zitat Pittet V et al. Information needs and concerns of patients with inflammatory bowel disease: what can we learn from participants in a Bilingual Clinical Cohort? PloS one 2016;11:e0150620.PubMedPubMedCentralCrossRef Pittet V et al. Information needs and concerns of patients with inflammatory bowel disease: what can we learn from participants in a Bilingual Clinical Cohort? PloS one 2016;11:e0150620.PubMedPubMedCentralCrossRef
53.
Zurück zum Zitat Vasudevan A, Arachchi A, van Langenberg DR. Assessing patient satisfaction in inflammatory bowel disease using the QUOTE-IBD survey: a small step for clinicians, a potentially large step for improving quality of care. J Crohn’s Colitis 2013;7:e367–e374.CrossRef Vasudevan A, Arachchi A, van Langenberg DR. Assessing patient satisfaction in inflammatory bowel disease using the QUOTE-IBD survey: a small step for clinicians, a potentially large step for improving quality of care. J Crohn’s Colitis 2013;7:e367–e374.CrossRef
54.
Zurück zum Zitat Vaucher C et al. Patients and gastroenterologists’ perceptions of treatments for inflammatory bowel diseases: do their perspectives match? Scand J Gastroenterol 2016;51:1056–1061.PubMedCrossRef Vaucher C et al. Patients and gastroenterologists’ perceptions of treatments for inflammatory bowel diseases: do their perspectives match? Scand J Gastroenterol 2016;51:1056–1061.PubMedCrossRef
55.
Zurück zum Zitat Cullen G et al. Perceptions of medication safety among patients with inflammatory bowel disease. Scand J Gastroenterol 2010;45:1076–1083.PubMedCrossRef Cullen G et al. Perceptions of medication safety among patients with inflammatory bowel disease. Scand J Gastroenterol 2010;45:1076–1083.PubMedCrossRef
56.
Zurück zum Zitat Wong S et al. The information needs and preferences of persons with longstanding inflammatory bowel disease. Can J Gastroenterol 2012;26:525–531.PubMedPubMedCentralCrossRef Wong S et al. The information needs and preferences of persons with longstanding inflammatory bowel disease. Can J Gastroenterol 2012;26:525–531.PubMedPubMedCentralCrossRef
57.
Zurück zum Zitat Catalán-Serra I et al. Information resources used by patients with inflammatory bowel disease: satisfaction, expectations and information gaps. Gastroenterol Hepatol 2015;38:355–363.PubMedCrossRef Catalán-Serra I et al. Information resources used by patients with inflammatory bowel disease: satisfaction, expectations and information gaps. Gastroenterol Hepatol 2015;38:355–363.PubMedCrossRef
58.
Zurück zum Zitat Khan S et al., Unmet communication and information needs for patients with IBD: implications for mobile health technology. Brit J Med Med Res, 2016;12(3). Khan S et al., Unmet communication and information needs for patients with IBD: implications for mobile health technology. Brit J Med Med Res, 2016;12(3).
59.
Zurück zum Zitat Politi P et al. Communication of information to patients with inflammatory bowel disease: A European Collaborative Study in a multinational prospective inception cohort. J Crohn’s and Colitis 2008;2:226–232.CrossRef Politi P et al. Communication of information to patients with inflammatory bowel disease: A European Collaborative Study in a multinational prospective inception cohort. J Crohn’s and Colitis 2008;2:226–232.CrossRef
60.
Zurück zum Zitat Quinn CC et al. The telemedicine for patients with inflammatory bowel disease (TELE-IBD) clinical trial: qualitative assessment of participants’ perceptions. J Med Int Res 2019;21:e14165. Quinn CC et al. The telemedicine for patients with inflammatory bowel disease (TELE-IBD) clinical trial: qualitative assessment of participants’ perceptions. J Med Int Res 2019;21:e14165.
61.
Zurück zum Zitat McCombie A, Gearry R, Mulder R. Preferences of inflammatory bowel disease patients for computerised versus face-to-face psychological interventions. J Crohn’s and Colitis 2014;8:536–542.CrossRef McCombie A, Gearry R, Mulder R. Preferences of inflammatory bowel disease patients for computerised versus face-to-face psychological interventions. J Crohn’s and Colitis 2014;8:536–542.CrossRef
62.
Zurück zum Zitat Baars JE et al. Patients’ preferences regarding shared decision-making in the treatment of inflammatory bowel disease: results from a patient-empowerment study. Digestion 2010;81:113–119.PubMedCrossRef Baars JE et al. Patients’ preferences regarding shared decision-making in the treatment of inflammatory bowel disease: results from a patient-empowerment study. Digestion 2010;81:113–119.PubMedCrossRef
63.
Zurück zum Zitat Gonczi L et al. Quality of care indicators in inflammatory bowel disease in a tertiary referral center with open access and objective assessment policies. Digest Liver Dis Off J Ital Soc Gastroenterol Ital Assoc Study Liver 2018;50:37–41. Gonczi L et al. Quality of care indicators in inflammatory bowel disease in a tertiary referral center with open access and objective assessment policies. Digest Liver Dis Off J Ital Soc Gastroenterol Ital Assoc Study Liver 2018;50:37–41.
64.
Zurück zum Zitat Nene S et al. Benefits of implementing a rapid access clinic in a high-volume inflammatory bowel disease center: Access, resource utilization and outcomes. World J Gastroenterol 2020;26:759–769.PubMedPubMedCentralCrossRef Nene S et al. Benefits of implementing a rapid access clinic in a high-volume inflammatory bowel disease center: Access, resource utilization and outcomes. World J Gastroenterol 2020;26:759–769.PubMedPubMedCentralCrossRef
65.
Zurück zum Zitat Vavricka SR et al. Systematic assessment of factors influencing preferences of Crohn’s disease patients in selecting an anti-tumor necrosis factor agent (CHOOSE TNF TRIAL). Inflamm Bowel Dis 2012;18:1523–1530.PubMedCrossRef Vavricka SR et al. Systematic assessment of factors influencing preferences of Crohn’s disease patients in selecting an anti-tumor necrosis factor agent (CHOOSE TNF TRIAL). Inflamm Bowel Dis 2012;18:1523–1530.PubMedCrossRef
66.
Zurück zum Zitat Rubin DT et al. Impact of ulcerative colitis from patients’ and physicians’ perspectives: results from the UC: NORMAL survey. Inflamm Bowel Dis 2009;15:581–588.PubMedCrossRef Rubin DT et al. Impact of ulcerative colitis from patients’ and physicians’ perspectives: results from the UC: NORMAL survey. Inflamm Bowel Dis 2009;15:581–588.PubMedCrossRef
67.
Zurück zum Zitat McDermott E et al. Patient education in inflammatory bowel disease: a patient-centred, mixed methodology Study. J Crohns Colitis 2018;12:419–424.PubMedCrossRef McDermott E et al. Patient education in inflammatory bowel disease: a patient-centred, mixed methodology Study. J Crohns Colitis 2018;12:419–424.PubMedCrossRef
68.
Zurück zum Zitat Reich J et al. Social media use and preferences in patients with inflammatory bowel disease. Inflamm Bowel Dis 2019;25:587–591.PubMedCrossRef Reich J et al. Social media use and preferences in patients with inflammatory bowel disease. Inflamm Bowel Dis 2019;25:587–591.PubMedCrossRef
69.
Zurück zum Zitat Reich J et al. A survey of social media use and preferences in patients with inflammatory bowel disease. Inflamm Bowel Dis 2016;22:2678–2687.PubMedCrossRef Reich J et al. A survey of social media use and preferences in patients with inflammatory bowel disease. Inflamm Bowel Dis 2016;22:2678–2687.PubMedCrossRef
70.
Zurück zum Zitat Yoo YS, Cho OH, Cha KS. Disease-related knowledge and information needs among inflammatory bowel disease patients in Korea. Gastroenterol Nurs 2015;38:455–463.PubMedPubMedCentralCrossRef Yoo YS, Cho OH, Cha KS. Disease-related knowledge and information needs among inflammatory bowel disease patients in Korea. Gastroenterol Nurs 2015;38:455–463.PubMedPubMedCentralCrossRef
71.
Zurück zum Zitat Bilgrami Z et al. Effect of telemedicine for inflammatory bowel disease on patient activation and self-efficacy. Digest Dis Sci 2020;65:96–103.PubMedCrossRef Bilgrami Z et al. Effect of telemedicine for inflammatory bowel disease on patient activation and self-efficacy. Digest Dis Sci 2020;65:96–103.PubMedCrossRef
72.
Zurück zum Zitat Chudy-Onwugaje K et al. Age modifies the association between depressive symptoms and adherence to self-testing with telemedicine in patients with inflammatory bowel disease. Inflamm Bowel Dis 2018;24:2648–2654.PubMedPubMedCentralCrossRef Chudy-Onwugaje K et al. Age modifies the association between depressive symptoms and adherence to self-testing with telemedicine in patients with inflammatory bowel disease. Inflamm Bowel Dis 2018;24:2648–2654.PubMedPubMedCentralCrossRef
Metadaten
Titel
Patient Perspectives and Expectations in Inflammatory Bowel Disease: A Systematic Review
verfasst von
Alex Al Khoury
Bhairavi Balram
Talat Bessissow
Waqqas Afif
Lorant Gonczi
Maria Abreu
Peter L. Lakatos
Publikationsdatum
21.05.2021
Verlag
Springer US
Erschienen in
Digestive Diseases and Sciences / Ausgabe 6/2022
Print ISSN: 0163-2116
Elektronische ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-021-07025-y

Weitere Artikel der Ausgabe 6/2022

Digestive Diseases and Sciences 6/2022 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.